











doi:10.101Treatment with Plerixafor in non-Hodgkin’s
Lymphoma and Multiple Myeloma Patients to Increase
the Number of Peripheral Blood Stem Cells When Given
a Mobilizing Regimen of G-CSF: Implications for the
Heavily Pretreated Patient
Patrick Stiff,1 Ivana Micallef,2 Philip McCarthy,3 Margarida Magalhaes-Silverman,4
Daniel Weisdorf,5 Mary Territo,6 Karin Badel,7 Gary Calandra7We investigated the efficacy and toxicity of combining granulocyte-colony stimulating factor (G-CSF) at stan-
dard doses with plerixafor, a CXCR4 inhibitor, to mobilize stem cells in patients with non-Hodgkin’s lym-
phoma (NHL) and multiple myeloma (MM). Patients with NHL and MM underwent mobilization with G-
CSF (10 mg/kg/day) for up to 9 days and plerixafor (240 mg/kg/day), which started on the evening of day 4.
Apheresis began on day 5 and continued daily until either $5  106 CD34/kg were collected or to a maxi-
mum of 5 aphereses. Toxicities, increase in circulating CD34 cells/mL before and after the first dose of pler-
ixafor, percentage of patients collecting$5 106 CD34/kg, total CD34 cells/kg collected, engraftment, and
exploratory efficacy analyses in heavily pretreated patients were examined. Six sites enrolled 49 patients
(NHL, 23; MM, 26). All completed mobilization and 47 of 49 (96%) underwent transplant. Circulating
CD34 cells/mL increased by 2.5-fold (1.3-6.0-fold) after the first plerixafor dose. The median CD34 cells/
kg collected was 5.9  106 (1.5-22.5) in 2 (1-5) days of aphereses. Median days to neutrophil and platelet
engraftment were 11 (8-16) and 14.5 (7-39) days, respectively. Adverse events primarily were mild nausea
and diarrhea (n 5 24). Twenty-eight (57%) were identified as heavily pretreated patients. Their median
fold increase in circulating CD34 cells/mL was 2.5 (1.4-5.0) after plerixafor, similar to minimally pretreated
patients. Plerixafor and G-CSF increased circulating CD34 cells/mL and led to the adequate collection of
stem cells for autotransplant in 96% of the patients. This combination may have particular value in heavily
pretreated patients.
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Primitive hematopoietic stem cells (HSC), capable
of restoring hematopoiesis after lethal marrow injury,
have long been known to circulate in the peripheral
blood of animals, nonhuman primates, and humans
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as measured by the CD34 assay, into the circulation
from the steady state [3]. However, subsequent studies
indicated that up to 30% of patients undergoing auto-
transplants for relapsed/refractory non-Hodgkin’s
lymphoma (NHL) and Hodgkin’s lymphoma fail to
have sufficient CD341 cells, that is, $2  106 cells/
kg, collected to ensure prompt hematopoietic recon-
stitution [4-8]. In these cases, transplants can be can-
celled because of disease progression associated with
the attendant delays in remobilization.
To facilitate stem cell mobilization a bicyclam
molecule, plerixafor (AMD3100), a reversible inhibi-
tor of HSC adhesion to stromal cells mediated through
CXCR4’s binding to stromal-derived factor-1a (SDF-
1a) was developed [9]. This agent led to rapid mobili-
zation of HSC in murine models [10] and subsequently
in healthy human volunteers [11,12] and patients [13]
when administered subcutaneously. Compared to249
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mobilization of human HSC as measured by nonobese
diabetic/severe combined immune deficiency (NOD/
SCID) spleen repopulating cells in volunteers who
received plerixafor [10]. The initial Phase I/II clinical
trial that compared G-CSF alone with the combina-
tion of plerixafor plus G-CSF, in which all patients
served as their own controls indicated that this combi-
nation mobilized a median of 4.4-fold (1.1-54.4) more
CD341 cells per day of apheresis as compared to
G-CSF alone [14].
Based on these initial results, this Phase II study of
the combination of plerixafor and G-CSF to mobilize
peripheral blood stem cells (PBSC) was developed to
explore its utility in unselected patients with NHL
and MM. In addition, exploratory analyses were per-
formed on heavily pretreated patients who are typically
considered as poor mobilizers as defined by prior stud-
ies to determine the relative value of this novel combi-
nation in this group.PATIENTS AND METHODS
Patient Eligibility
This was a single arm, multicenter Phase II study
of the safety and efficacy of plerixafor (240 mg/kg)
with G-CSF (10 mg/kg), for the collection of PBSC
for autologous transplantation. Patients with NHL
and MM, aged 18-70 years, undergoing a first PBSC
mobilization procedure were eligible. Other require-
ments included: no more than 3 prior regimens, 4
weeks from last chemotherapy, an Eastern Coopera-
tive Group performance status of 0 or 1, a white blood
cell count (WBC) of .3.0  109/L, an absolute neu-
trophil (ANC) count of.1.0  109/L, a platelet count
of .100  109/L, a serum creatinine of #2.2 mg/dL,
liver function tests less than twice the upper limit of
normal, a left ventricular ejection fraction (LVEF) of
.45%, and an FEV1 or DLCO of.60% and 45%, re-
spectively. Exclusions included central nervous system
involvement, temperature .38C, .175% of ideal
body weight, and a history of ventricular arrhythmias.
The study protocol was approved by each center’s
institutional review board. The study was conducted in
compliance with Declaration of Helsinki and Good
Clinical Practice guidelines. All patients provided
written informed consent and could withdraw from
the study at any time.Mobilization Regimen
A schematic diagram of the mobilization schema is
provided in Figure 1. Patients received G-CSF at 10
mg/kg subcutaneously for up to 9 days, as per local
practice. Plerixafor 240 mg/kg was administered subcu-
taneously in the evening prior to each day of apheresisbeginning on the evening of day 4 of G-CSF adminis-
tration. Apheresis was initiated 10-11 hours after each
dose of plerixafor starting on day 5 of G-CSF mobili-
zation and consisted of 3 blood volumes 610%. This
regimen was given for up to 4 more days or until $5
 106 CD341 cells/kg was collected. A minimum of
2 106 CD34/kg collected on study treatment was re-
quired to proceed to transplantation. If insufficient
PBSC were obtained from the 5 apheresis collections,
cells could be retained, pooled, and transplanted after
a second mobilization at a later date at the investiga-
tor’s discretion.
Transplantation Procedure
Patients underwent myeloablative therapy and
PBSC reinfusion as determined locally. They were as-
sessed daily for the first 30 days and then at 3, 6, and 12
months after transplantation. Patients with MM could
undergo tandem autotransplants if sufficient PBSC
were collected for the 2 transplant procedures prior
to the first transplant.
Criteria for Evaluation
Efficacy parameters included: circulating CD341
cell count before and after the first dose of plerixafor,
CD341 cell yield by apheresis, neutrophil, and platelet
engraftment, and graft durability. Criteria for engraft-
ment were determined locally but in the majority of
patients were defined as the first of 3 consecutive
days where the ANC was.500 cells/mL and in all cases
for platelet engraftment was defined as the first day of
a untransfused platelet count of .20  109/L.
The primary objective of the study was to deter-
mine the safety of the plerixafor/G-CSF combination.
Three periods were analyzed for safety: (1) mobiliza-
tion; (2) transplantation, defined as the day from the
initiation of high dose therapy to the date of platelet
and ANC engraftment; and (3) the period from en-
graftment through 12 months posttransplant. Safety
was evaluated by adverse event (AE) monitoring, and
physical and laboratory evaluations.
The primary efficacy endpoint for the study was to
determine if NHL and MM patients mobilized by the
plerixafor/G-CSF combination had a$2-fold increase
in circulating CD341 cells after the first dose of pler-
ixafor. The fold increase was defined as the relative in-
crease in blood CD34 cell count pre- and
postplerixafor dosing; specifically, the fold increase
was calculated as a ratio of preapheresis blood CD34
cell count (10-11 hours postplerixafor dosing) divided
by the preplerixafor dosing blood CD34 cell count.
Other efficacy measures were: the number of days of
apheresis to collect the cumulative target yield of $5
 106 CD341 cells/kg for transplantation, successful
engraftment of neutrophils after transplant, and the
number of days to neutrophil engraftment. Planned
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9
Mobilization Collection
Screening
Daily dose of G-CSF (10 mcg/kg/day)
Apheresis session (3 Volume ±10% apheresis)
Plerixafor (240 mcg/kg/day SQ)
Stem Cell Mobilization Procedure
Figure 1. Mobilization schema.
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graftment and number of days to engraftment of plate-
lets, the durability of engraftment at 3, 6, and 12
months after transplantation and the total number of
CD341 cells/kg collected during apheresis. Graft du-
rability was defined as maintenance of normal blood
counts at 3, 6, and 12 months posttransplantation.
Statistical Methods
This was an intent-to-treat study with no adjust-
ments to the data for dealing with missing values.
Fifty-five5 patients with NHL and MM were planned
for this study, from 8 transplant centers. A patient who
did not complete either the first 4 days of G-CSF and/
or did not receive plerixafor as per the protocol was to
be replaced. The sample size was chosen to provide ad-
equate numbers of patients from the various sites to
provide data in preparation for Phase III trials in these
diseases.
Exploratory Analyses Based on Prior Therapy
and Circulating CD341 Cell Counts
We analyzed outcome based on the patient’s prior
therapy. Heavily pretreated patients were defined as
those who had received 10 or more total cycles of che-
motherapy, had received platinum-based chemother-
apy either at diagnosis or at the time of relapse, or
had received any dose of radiation to bone marrow
bearing sites, these patients have historically been
poor mobilizers [15-30]. In addition, we analyzed out-
come for patients with #10 circulating CD341 cells/
mL just before the first dose of plerixafor therapy on
the evening of the fourth day of G-CSF therapy,
because circulating CD341 cells is another factor
that has been found to be predictive for poor stem
cell collection [21].RESULTS
Patient Characteristics
A total of 49 patients were enrolled at 6 centers: 23
with NHL and 26 with myeloma (Table 1). Two cen-ters enrolled 15 patients each, 1 center enrolled 10 pa-
tients, 1 center enrolled 5 patients, 1 center enrolled 3
patients, and 1 center enrolled 1 patient. The median
time from confirmed diagnosis to study entry was
24.0 months for the NHL and 6.5 months for the
MM groups. All patients received prior pretreatment.
All patients in the NHL group had received chemo-
therapy, whereas 8 in the MM group received only
dexamethasone with or without thalidomide. The me-
dian number of cycles of chemotherapy was 8 in the
NHL group and 3 in the MM group. Seven patients
in the NHL group (30.4%) and 8 in the MM group
(30.8%) had received prior radiotherapy. All but 7
(30.4%) patients in the NHL group were transplanted
after second-line chemotherapy, whereas 20 (76.9%)
patients in the MM group entered after initial therapy.
All patients completed the G-CSF mobilization
phase and received at least 1 dose of plerixafor. A total
of 47 (96%) patients (22 NHL, 25 MM) received
a transplant on study. One of the 2 remaining with
NHL did not complete the plerixafor treatment be-
cause of thrombocytopenia and poor stem cell collec-
tion and 1 patient with MM completed protocol
mobilization therapy but received a transplant of cells
pooled with those from a previous off-study mobiliza-
tion, even though this patient achieved the CD341
cells/kg target specified in the protocol.Mobilization Data
Surrogate efficacy of CD341 cell mobilization by
plerixafor and G-CSF was demonstrated by a median
2.5-fold (range: 1.3-6.0) increase in circulating
CD341 cells/mL from preplerixafor administration
on the evening of day 4 of G-CSF mobilization to pre-
apheresis 10-11 hours postplerixafor administration as
shown in Table 2. Although baseline preplerixafor
CD341 cells/mL were lower for the NHL group
(16.0 versus 41.5), 20 of 23 (87%) in this group had
a .2-fold increase in CD34/mL versus 17 of 26
(65%) for the MM group.
All patients underwent at least 1 apheresis. The
median number of CD341 cells/kg collected was 5.9
 106 (95% confidence interval [CI] of the mean







Age (median, range) 56.0 (40-67) 57.5 (42-74) 57.0 (40-74)
Female (n, %) 9 (39.1%) 10 (38.5%) 19 (38.8%)
Months since diagnosis
(median, range)
24.0 (5-81) 6.5 (3-132) 11.0 (3-132)
Prior cytotoxic
chemotherapy (n, %)
23 (100%) 16 (61.5%) 39 (79.6%)
Prior radiotherapy (n, %) 7 (30.4%) 8 (30.8%) 15 (30.6%)
First remission (n, %) 7 (36.4%) 20 (76.9%) 27 (55.1%)
Extensive radiotherapy (n, %) 11 (47.8%) 10 (38.5%) 21 (57.1%)
NHL indicates non-Hodgkin’s lymphoma; MM, multiple myeloma; ALL,
acute lymphoblastic leukemia.
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collect this dose was 2 (1-5), and was similar for
NHL and MM patients (Table 2). A total of 11 of 49
(22.4%) collected the target CD341 cell dose of $5
 106 CD341 cells/kg in a single apheresis, including
3 NHL and 8 MM patients. In contrast, 12 patients re-
quired 5 aphereses, including 9 patients with NHL and
3 with MM. 38 of 49 patients (77.6%) collected $5 
106 CD341 cells/kg and 47 of 49 patients (95.9%) col-
lected $2  106 CD341 cells/kg, the minimum dose
needed for transplant. Two patients in the NHL group
did not reach the minimum number of cells for trans-
plant. One collected 1.45  106 CD341 cells/kg in the
maximum 5 aphereses and the second collected 1.9 
106 CD341 cells/kg in 3 aphereses but stopped mobi-
lization because of thrombocytopenia. Cumulative
daily apheresis yields are shown in Figure 2.Transplant Procedures
All patients received standard ablative preparative
regimens: for NHL, these were BCV (BCNU, etopo-
side, and cyclophosphamide) in 12 patients [22,23], to-
tal-body irradiation (TBI) with etoposide and
cyclophosphamide in 9 patients [23], BEAM
(BCNU, cytosine arabinoside, etoposide, and melpha-
lan) in 7 patients [24], and busulfan and cyclophospha-
mide in 2 patients [25]. For the patients with MM,Table 2. Mobilization Data
NHL (n 5 23)
Peripheral blood CD34 cells/mL
Pre-Plerixafor 16.0 (2.0-57.0)
Post-Plerixafor* 43.0 (5.3–124.0)
N-fold increase in CD34 cells/mL 2.5 (1.3-6.0)
$2-fold increase (n, %) 20 (87.0%)
Apheresis days 3 (1-5)
Total CD34 cells/kg 5.2 (1.5-18.9)
Apheresis yield
$5  106 CD34 cells/kg (n, %) 13 (56.5%)
$2  106 CD34 cells/kg (n, %) 21 (91.3%)
NHL indicates non-Hodgkin’s lymphoma; MM, multiple myeloma; ALL, acute l
Data are presented as median (range).
*Prior to the first apheresis.busulfan and cyclophosphamide was used in 5 patients,
BEAM in 1 patient, and single-agent melphalan in 20
patients [26]. Two patients with MM received tandem
transplants, both with melphalan.
The median time to ANC and platelet engraftment
were 11 (8-16) and 14.5 (7-39) days, respectively. One-
year survival for the entire group transplanted on study
was 91.5% (43 of 47 patients). Graft durability was as-
sessed at 12 months posttransplant in 44 of the 47
transplanted patients. Three patients died prior to
the 6 month follow-up time period and were not eval-
uated for graft durability. One patient had received
chemotherapy at approximately 9 months posttrans-
plant for relapse. None has developed myleodysplastic
syndrome or acute myeloid leukemia.Safety
All 49 patients in the study experienced at least 1
AE. Of the AEs, 53.1% were considered to be mild,
14.3% were moderate, and 14.3% were considered se-
vere. Overall, 40 patients (81.6%) experienced AEs
that were possible, probably or definitely related to
study drug. The most common AEs seen during mobi-
lization are listed in Table 3. These AEs primarily were
gastrointestional disorders that consisted of diarrhea
and nausea in 28 patients, injection site reactions in 7
patients, increased blood alkaline phosphatase in 8 pa-
tients, anemia in 5 patients, and thrombocytopenia in 5
patients.
Two patients discontinued study treatment be-
cause of AEs that were considered either probably
not related or not related to study treatment. The first
because of thrombocytopenia and poor stem cell col-
lection as noted above, and the second after the first
dose of plerixafor because of moderate anxiety, chest
pain, nausea, diaphoresis, shortness of breath, depres-
sion, and tremors.
Nine patients experienced thrombocytopenia dur-
ing apheresis. In 1, it was felt to be related to study
drug; this resolved with completion of the transplant.
For the remaining 8, the investigators felt that theMM (n 5 26) ALL (n 5 49)
41.5 (3.6-209.0) 24 (2.0–209.0)
78.9 (10.8–531.0) 56 (5.3-531.0)
2.6 (1.4-5.0) 2.5 (1.3-6.0)
17 (65.4%) 37 (75.5%)
2 (1-5) 2 (1-5)
11.1 (4.4-22.5) 5.9 (1.5-22.5)
25 (95.2%) 38 (77.6%)
26 (100%) 47 (95.9%)
ymphoblastic leukemia.
Table 3. Adverse Events Seen during Mobilization
(n, %) Total Moderate Severe
Gastrointestinal 28 (57%) 4 (8.2%) 0
Diarrhea 19 (38.8%) 3 (6.1%) 0
Nausea 9 (18.4%) 1 (2.1%) 0
Abdominal pain 3 (6.1%) 1 (2.1%) 0
Injection site erythema 7 (14.3%) 0 0
Alkaline phosphatase
elevations
8 (16.3%) 2 (4.1%) 0
Thrombocytopenia 5 (16.2%) 3 (6.1%) 1 (2.0%)
Lymphopenia 6 (12.2%) 0 6 (12.2%)
Insomnia 3 (6.1%) 1 (2.0%) 0
Figure 2. Number of apheresis days to reach cell count target of 5 
106 CD34/kg for all patients, and the non-Hodgkin’s and MM subsets.





Number of patients 28 21
N-fold increase in circulatory
CD34 cells/mL (median, range)
2.6 (1.3-6.0) 2.5 (1.4-5.0)
Apheresis days (median, range) 3 (1-5) 2 (1-5)
Total CD34  106 cells/kg
collected (median, range)
5.4 (2.9-12.9) 5.2 (1.4-12.5)
Apheresis yield
$5  106 CD34  106/kg (n, %) 14 (67%) 16 (58%)
*Defined as patients who had received 10 or more total cycles of che-
motherapy, had received platinum-based chemotherapy either at diag-
nosis or at the time of relapse, and/or had received any dose of
radiation to bone marrow bearing sites [15].
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only possibly related (4) to study drug (rather the
apheresis caused depletion of circulating platelets).
There were 9 patients with normal liver enzymes at
baseline who had elevated values 24 hours after the
last apheresis; all resolved. Two were considered to
be clinically significant by the investigators.
A total of 47 severe adverse events (SAE) were re-
ported for 18 patients. None were considered to be re-
lated to study drug. One occurred in Period 1 and was
related to heparin-induced thrombocytopenia. The
most common SAE, experienced by 6 patients, was
infection that occurred during period 2. Five were re-
lated to gastrointestional complications during trans-
plant (vomiting and diarrhea) and 5 because of
general conditions, most notably pyrexia.
Three patients died during the 1 year follow-up
period after transplant. One NHL patient died at 2
months posttransplant because of failure to thrive.
The second died at 4 months posttransplant of an
aggressive respiratory illness. The third patient died
unexpectedly at 4 months posttransplant with pneu-
monia. The 1 year survival rate for the entire group
was 93.9%.
Impact of Prior Therapy and Circulating CD34
cells on Mobilization Success
Of the 49 patients, 28 (18 NHL, 10 MM) or 57.1%
met criteria for being considered as heavily pretreated
patients. Their mobilization results are shown in
Table 4. The median fold increase in CD34/mL for
heavily pretreated and nonheavily pretreated patients
after the first dose of plerixafor was similar, 2.6 (1.0-
6.0) and 2.5 (1.4-5.0), respectively. The median num-
ber of aphereses for the heavily pretreated patients
was 3 (1-5), and the total median yield of CD34
cells/kg was 5.4  106/kg (2.9-12.9). In contrast, the
nonheavily pretreated patients underwent a median
of 2 (1-5) aphereses, which yielded a median of 5.2 
106/kg (1.4-12.5) of CD34 cells. Durability of collec-tions was maintained for each group with day 2 and 3
collections for each group being 2.08 and 3.37 
106/kg for day 2 and 0.98 and 1.64  106/kg for day
3, respectively. Cumulative daily apheresis yields are
shown in Figure 3 for the 2 groups.
ANC engraftment occurred at 14 (8-16) and 12 (9-
15) days and platelet engraftment at 13 (8-39) and 16
(9-26) days, respectively, for the heavily pretreated
and the nonheavily pretreated groups.
Circulating CD34 cells and Mobilization Success
Ten patients in the entire study had peripheral
blood counts\10 CD34/mL just before the first dose
of plerixafor, a marker for poor mobilization. All pa-
tients in this group underwent 5 aphereses; yielding
4.2  106/kg CD341 cells/kg; 9 of 10 had $2.5 
106/kg CD341 cells/kg collected.DISCUSSION
Plerixafor, a reversible bicyclam inhibitor of HSC
binding to SDF-1a on marrow stromal cells via the
chemokine receptor 4 (CXCR4) on HSC [10,27], has
previously been shown to mobilize PBPC when used
alone or in combination with G-CSF [4-14,28]. The
combination was shown to mobilize more stem cells
than did G-CSF alone in the first Phase I/II study
[14]. In that study, the plerixafor dose that promoted
optimal mobilization (240 mg/kg), and the timing
Figure 3. Number of apheresis day to reach CD34 cell target of 5 
106 CD34/kg for heavily versus nonheavily pretreated patients.
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The authors found that stem cells collected using
this combination rapidly reconstituted hematopoiesis
after an ablative regimen, similar to that seen using
cells collected with G-CSF alone.
This multicenter Phase II trial of 49 patients auto-
transplanted for NHL (n5 23) and myeloma (n5 26)
at 6 centers verified these preliminary results and per-
mitted an analysis of those heavily pretreated patients
who comprise a group that typically mobilize poorly
with standard cytokine regimens. As predicted in pre-
clinical models [9-11], an overall 2.6-fold increase in
circulating CD34 cells was seen after the first dose of
plerixafor, and 47 of 49 (95.9%) collected a minimum
cell dose of $2  106 CD341 cells/kg to proceed to
transplant. Thirty-eight (77.6%) patients in fact col-
lected $5  106 CD341 cells/kg, and 13 (26.5%)
achieved this target in a single apheresis. Only 2
NHL patients (4.1%) failed to collect the needed 2 
106 CD341 cells/kg to proceed to transplant; one col-
lected only 1.48  106/kg after 5 aphereses and the
other in whom 1.88 106/kg were collected in 3 apher-
eses, stopped early. The median time to ANC and
platelet engraftment was similar to that seen for G-
CSF mobilized stem cells and the grafts were durable
at 1-year after transplant. These results prompted the
Phase III trials of this agent in these 2 patient groups.
The safety profile of plerixafor with G-CSF was
similar to that of the initial Phase I/II trial [14]. Local
injection site reactions were common, and gastrointes-
tional complications of diarrhea and abdominal cramp-
ing, which occur shortly after the administration of the
drug, were usually mild and of short duration. No
drug-related SAEs were reported, and no cases of late
graft failure were reported up to 12 months follow-up.
Numerous studies indicated that patients such as
those treated here would have a mobilization failure
rate of 20% to 30% and not the 4.1% that was seen
[8,17,20,29]. Based on this apparent benefit, we retro-
spectively analyzed the outcome of heavily pretreatedpatients typically considered to be ‘‘poor mobilizers’’
in other mobilization studies [15-20]. In these studies,
treatment with G-CSF alone resulted in mobilization
failure rate of up to 46% [15-20]. Using these criteria
from the literature we found that 28 of 49 (57.1%) pa-
tients in this study were heavily pretreated, and thus,
typically considered to be ‘‘poor mobilizers.’’ These
patients were indeed ‘‘poor mobilizers’’ as they had
a low CD34/mL (18 cells/mL) after 4 days of G-CSF.
However, they had the same fold increase (2.6-fold)
as the nonheavily pretreated group (2.5-fold), and
67% of these heavily pretreated patients were able to
collect the target of 5 106 CD341 cells/kg. Most im-
portantly, all were able to collect the minimum 2 106
CD341 cells/kg needed to move forward with trans-
plant. Engraftment times for these heavily treated pa-
tients were similar to the nonheavily pretreated
patients, attesting to the quality of the stem cells col-
lected.
Although any comparison to the literature should
be considered as preliminary, further evidence attest-
ing to the value of this novel combination in heavily
pretreated patients is its ability to mobilize sufficient
stem cells for transplant in the subgroup that had a pre-
apheresis CD34 cell count after day 4 of G-CSF of
\10 cells/mL, a level below which most centers use
to halt the mobilization process. A total of 10 patients
met the criteria in this study. Their mean yield after 5
apheresis was 4.2 (1.4-8.4)  106 CD341 cells/kg and
all but 1 patient collected the minimum safe dose for
transplant of 2  106 CD341 cells/kg.
The addition of chemotherapy to G-CSF is also
frequently used for peripheral blood stem cell mobili-
zation and has generally been reported to improve
CD341 cell collection [30-33]. However, this increase
in CD341 cell collection is limited by the toxicity of
chemotherapy, the need for hospitalizations in some
patients, and the unpredictability of the optimal time
to initiate apheresis [34,35]. Additionally, this regimen
may not always be more effective in the heavily pre-
treated patients [33]. Based on this study, it appears
that this new combination of plerixafor and G-CSF
mobilization may have several advantages over chemo-
therapy/G-CSF mobilization. Apart from being rela-
tively well tolerated, our data suggests that it may
decrease the concern for successful mobilization in
the majority of heavily pretreated patients, thereby
minimizing the need for and costs of a second mobili-
zation procedure for those 20% to 30% who do not
collect sufficient stem cells to proceed directly to
transplant. By increasing stem cell yields, this combi-
nation may also decrease the numbers of patients
who experience delayed platelet engraftment after en-
graftment as there is a well characterized correlation
between platelet engraftment and CD34 cell dose up
to at least 5  106 cells/kg [36]. This combination
also appears to facilitate the collection of sufficient
Biol Blood Marrow Transplant 15:249-256, 2009 255Plerixafor and G-CSF to Increase Peripheral Blood CD341 Cellsstem cells for several transplants, which remains the
standard of care for many patients with MM as sec-
ond-day yields are similar to that of the first day. Fi-
nally, it will permit the further exploration of CD34
dose on a variety of clinical outcome measures, includ-
ing quality of life and survival.ACKNOWLEDGMENTS
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